EcoDrugPlus

Melanocortin 4 Receptor

Ensembl ID : ENSDLEG00000003758
Gene Symbol: MC4R
1 Cross references
229 Possible Orthologues:

Melatonin Receptor 1b

Ensembl ID : ENSDLEG00000010941
Gene Symbol: MTNR1B
1 Cross references
107 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSDLEG00000011051
Gene Symbol: METAP2
3 Cross references
230 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSDLEG00000015738
Gene Symbol: MAPK1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSDLEG00000014759
Gene Symbol: MAPK10
1 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSDLEG00000020270
Gene Symbol: MAPK14
3 Cross references
293 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSDLEG00000014296
Gene Symbol: MAPK3
3 Cross references
199 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSDLEG00000011416
Gene Symbol: MAPK8
3 Cross references
292 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSDLEG00000017214
Gene Symbol: MAPK9
3 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSDLEG00000010364
Gene Symbol: MAP2K1
3 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSDLEG00000020230
Gene Symbol: MAP2K2
3 Cross references
269 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSDLEG00000008628
Gene Symbol: MAP3K1
3 Cross references
160 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).